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Abstract 84 
Systemic sclerosis (SSc) is an autoimmune disease characterized by fibrosis of skin and multiple 85 
organs of which the pathogenesis is poorly understood. Here we studied differentially expressed 86 
coding and non-coding genes in relation to SSc pathogenesis with a specific focus on antisense non-87 
coding RNAs. Skin biopsy-derived RNAs from fourteen early SSc patients and six healthy individuals 88 
were sequenced with ion-torrent and analysed using DEseq2.  89 
Overall, 4901 genes with a fold change >1.5 and a false discovery rate < 5% were detected in patients 90 
versus controls. Upregulated genes clustered in immunological, cell adhesion and keratin-related 91 
processes. Interestingly, 676 deregulated non-coding genes were detected, 257 of which were 92 
classified as antisense genes. Sense genes expressed opposite of these antisense genes were also 93 
deregulated in 42% of the observed sense-antisense gene pairs. The majority of the antisense genes 94 
had a similar effect sizes in an independent North American dataset with three genes (CTBP1-AS2, 95 
OTUD6B-AS1 and AGAP2-AS1) exceeding the study-wide Bonferroni-corrected ρ-value 96 
(PBonf<0.0023, Pcombined = 1.1x10-9, 1.4x10-8, 1.7x10-6, respectively). In this study, we highlight that 97 
together with coding genes, (antisense) long non-coding RNAs are deregulated in skin tissue of SSc 98 
patients suggesting a novel class of genes involved in pathogenesis of SSc.  99 
 100 
 101 
 102 
 103 
 104 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
4 
 
INTRODUCTION 105 
Systemic sclerosis (SSc) is a heterogeneous complex autoimmune disease affecting connective 106 
tissues. Its pathogenesis remains elusive, but patients harbour vascular changes like Raynaud’s 107 
phenomenon, autoimmunity with the presence of distinct autoantibodies, activation of both innate and 108 
adaptive immunity and active deposition of extracellular matrix leading to fibrosis. Progression of 109 
vascular and fibrotic organ damage accounts for a large proportion of the chronic morbidity and 110 
mortality up to 25% in the first five years after diagnosis in SSc (Rubio-Rivas et al. 2014).  111 
 In order to further understand the processes involved in SSc pathophysiology, several groups have 112 
performed gene expression studies in peripheral blood and skin of SSc patients (Gardner et al. 2006; 113 
Pendergrass et al. 2012; Milano et al. 2008; Whitfield et al. 2003). These studies have revealed that 114 
gene expression profiles in skin from SSc patients not only differ from healthy skin but are associated 115 
with skin disease severity (Milano et al. 2008). Interestingly, several SSc-specific gene sets have been 116 
identified which include fibrosis related pathways involved in skin thickening (TGF-β related genes, 117 
collagen genes) as well as immunological and keratin-related pathways (interferon genes, activated 118 
macrophage genes, chemokine-related genes and keratin genes) (Mahoney et al. 2015; Assassi et al. 119 
2015; Gardner et al. 2006; Mathes et al. 2014). These studies were all performed using microarrays, 120 
and focussed on the identification of protein coding genes and pathways that are differently regulated 121 
in SSc, and as a consequence missing an important component of non-coding genes involved in 122 
disease pathogenesis. With the use of next generation sequencing, transcriptomics studies can now 123 
shed light on the non-coding genome and the role of long non-coding RNAs (lncRNAs) in disease 124 
mechanisms. 125 
 lncRNAs represent an important layer of genome regulation and their role in the context of SSc is 126 
currently unknown. lncRNAs are transcripts over 200 nucleotides in length and come in diverse 127 
flavours including: antisense RNAs, long intergenic non-coding RNAs (lincRNAs) and pseudogenes 128 
(Derrien et al. 2012). Although the function of the majority of lncRNAs remains unknown, a role in 129 
regulating and shaping the genome has been proposed (Rinn JL 2013; Melé and Rinn 2016). 130 
Specifically, antisense RNAs can influence RNA levels of their sense counterpart (Faghihi and 131 
Wahlestedt 2010; Derrien et al. 2012; Chan et al. 2015; Peng et al. 2015; Kimura et al. 2013). In 132 
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diseases like SSc, where deregulated gene expression signatures are present, identification of such 133 
regulatory genes may represent interesting candidates as biomarkers or unlock novel treatment 134 
avenues. In addition, compared to coding genes, lncRNAs display higher tissue specificity in their 135 
expression patterns (Derrien et al. 2012). Recently, deregulated lncRNA expression has been 136 
described in the skin of patients with psoriasis (Gupta et al. 2016) and in the regulation of TGF-β 137 
mediated processes  (Richards et al. 2015) suggesting that lncRNAs may also be deregulated in skin 138 
of SSc patients. 139 
In order to extend the current knowledge of the gene expression signature in SSc, we have performed 140 
RNA sequencing on skin biopsies of SSc patients and healthy controls and investigated deregulated 141 
expression of both coding and non-coding genes. Moreover, main findings on non-coding genes were 142 
replicated in an independent dataset. 143 
 144 
RESULTS 145 
DE genes in SSc patients are enriched in immunological, cell activation and keratinization 146 
pathways and overlap with previous studies.  147 
In order to identify genes and pathways involved in SSc pathophysiology, we evaluated RNA 148 
expression levels in patients and controls. 4901 genes were DE with a minimum fold change of 1.5 149 
and FDR p-value below 0.05 (Supplementary File 2). Hierarchical clustering on basis of these DE 150 
genes separates patients from healthy controls with the exception of 1 patient which displays a 151 
normal-like expression pattern (Supplementary Figure 1). Pathway analysis of overexpressed genes 152 
shows an enrichment in the immune response, cell activation and keratinization pathways 153 
(Supplementary File 3). Cross comparison with DE genes from a recent publication by Assassi et al 154 
indicates a small highly consistent (>96%) overlap with the most prominent common pathways 155 
belonging to the immunological and cell adhesion related processes (Figure 1a-c, Supplementary File 156 
4).  157 
 158 
In-depth analysis of specific SSc-related gene sets highlights additional candidate genes 159 
implicated in SSc and an inflammatory gene signature. 160 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
6 
 
As an initial approach, we performed an in-depth analysis of several SSc gene sets which previously 161 
came forward from microarray studies including TGFβ signalling, collagen, keratin, interferon, 162 
alternative macrophage activation genes and chemokines (Figure 2, Supplementary File 1 and 163 
Supplementary File 5). Similar to our GO-term enrichment analysis, a clear increased TGFβ 164 
expression profile that is involved in many fibrotic processes was not observed in our patient 165 
population as only 5 out of 86 TGFβ signalling genes were significantly increased (Figure 2a). On the 166 
other hand, TGFβ-gene COMP was found increased in patients as similar to previous reports (Farina 167 
et al. 2009a; Assassi et al. 2015; Gardner et al. 2006). Moreover, many collagen and keratin 168 
associated genes are significantly increased in patients (Figure 2b and c). Also, 33 out of 97 genes 169 
from the interferon and macrophage gene sets were significantly increased in SSc patients (Figure 2d 170 
and e) indicating an increased inflammatory gene signature being present in early SSc patients 171 
(Assassi et al. 2015; Greenblatt et al. 2012; Mahoney et al. 2015). This observation is in line with 172 
previous studies showing that in early SSc (as is our population) the inflammatory signature 173 
is more prevalent (Assassi et al. 2015). Since skin paraffin sections were available for the patients 174 
under study, we stained skin sections for CD68, a marker for macrophages. In line with the observed 175 
inflammatory gene signature, clusters of macrophages were detected in the skin of SSc patients 176 
(Supplementary Figure 2). Besides these observations, several (to our knowledge previously 177 
unreported) genes including COL4A4, Keratin 4 and 9, TNFAIP3, CX3CR1, CXCL2 and PF4 were 178 
strongly deregulated in SSc patients (Figure 2b-k, Supplementary Table 1). 179 
 180 
Identification of DE lncRNAs in SSc skin biopsies in comparison to healthy controls. 181 
In addition to coding genes, RNA sequencing allows the query of non-coding genes. Among 15941 182 
annotated lncRNAs, 4171 were expressed in our skin biopsies. 676 lncRNAs were DE (FDR < 0.05) 183 
between SSc patients and healthy controls and show a clear differential expression signature (Figure 184 
3a). All 676 DE lncRNAs are listed in Supplementary File 6. Out of 676 lncRNA genes, 122 genes 185 
were decreased, while the expression of 554 genes was increased in SSc patients as compared to 186 
healthy controls. Interestingly, clustering analysis using different selection criteria of lncRNAs all 187 
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displayed a pattern where non-clinically active patients clustered within the patient population and 188 
separate from controls (Supplementary Figure 3). In total, 348 lncRNAs displayed over 2 fold 189 
differential expression and the top upregulated gene is CAPN10-AS1, an antisense lncRNA (Figure 190 
3b). Interestingly, among the 676 deregulated lncRNAs, the largest proportion (38%) belongs to the 191 
antisense gene category (Figure 3c). Antisense lncRNAs have recently been described to have 192 
important regulatory roles on their coding gene counterparts expressed in the sense direction 193 
(Pelechano and Steinmetz 2013; Werner 2013; Katayama et al. 2005; Villegas and Zaphiropoulos 194 
2015). The relevance of the antisense genes in our data set was therefore investigated.  195 
 196 
Identification of DE antisense genes in SSc patients and their link to sense coding genes. 197 
In order to gain further insight into the possible role of antisense RNAs in SSc, we focused our 198 
analysis on antisense genes of which a sense gene was annotated (also known as sense-antisense 199 
(SAS) gene pairs). Close proximity of antisense genes with sense genes have been linked to co-200 
expression and co-regulation within such a SAS gene pair (Villegas and Zaphiropoulos 2015; 201 
Katayama et al. 2005). Out of 257 DE antisense genes, 62 have an annotated sense gene. Interestingly, 202 
an important proportion (26 out of 62) of these SAS gene pairs includes both a significant DE 203 
antisense gene and a significant DE sense gene (FDR < 0.05) (Figure 3d). We further explored the 204 
relation between sense and antisense genes using correlation analysis by comparing the correlation of 205 
gene pairs where both genes are deregulated compared to gene pairs which were not deregulated in 206 
patients (consisting of gene pairs of which only one of the two genes was deregulated and of gene 207 
pairs of which neither the sense gene nor the antisense gene was deregulated in patients). Here high 208 
correlations (median r > 0.7) were observed for gene pairs significantly deregulated in SSc (SSc gene 209 
pairs) and were significantly higher in comparison with non SSc-deregulated gene pairs (P < 0.001) 210 
(Figure 3e). These data indicate that the identified antisense genes are either coexpressed with coding 211 
genes or involved in the regulation of their levels, illustrating a mechanism by which long non-coding 212 
(antisense) RNAs may play a role in SSc. 213 
In order to obtain further evidence for the involvement in SSc of the selected 26 antisense 214 
genes, we acquired gene expression values from an independent dataset where RNA sequencing had 215 
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been performed (14 SSc patients, 6 controls, Whitfield et al, unpublished data). 4 of the 26 genes were 216 
not present due to low expression in the independent dataset and were further excluded from the 217 
analysis. 12 out of 22 genes follow the same direction of association in both datasets (Table 1). Three 218 
antisense genes CTBP1-AS2, OTUD6B-AS1 and AGAP2-AS1 reached beyond the study-wide 219 
replication p-value threshold (P < 0.0023) (Table 1 and Figure 4a-c). Verification using an second 220 
experimental approach confirmed that these three genes are significantly deregulated ( (P < 0.01) 221 
Supplementary Figure 4). We confirmed the non-coding nature of these antisense genes using a 222 
coding potential calculator which showed an overall low coding potential for CTBP1-AS2, OTUD6B-223 
AS1 and AGAP2-AS1 (Supplementary Figure 5). We next evaluated the relationship of these non-224 
coding antisense genes with their paired sense gene across our patients and controls. Interestingly, the 225 
identified antisense genes show a strong correlation with their paired sense gene across the 20 226 
individuals, in particular for OTUD6B-AS1 and CTBP1-AS2 (r = 0.89, P < 0.001 and r = 0.79, P < 227 
0.001, respectively, Figure 4D-F). As skin is composed of many cell types we took advantage of 228 
available cell type specific expression datasets to gain further insight into which cell types may be 229 
relevant for these candidates. CTBP1 and CTBP1-AS2 levels also positively correlate across specific 230 
cell types and this correlation is highest in immune cells (r = 0.7, P <0.001) (Figure 5a). The 231 
OTUD6B gene pair is expressed in dermal and immune cells, and shows a correlation that was similar 232 
as observed across patients (r = 0.6-0.8, P<0.01) (Figure 5b). Interestingly, AGAP2 is only expressed 233 
in immune cells while AGAP2-AS1 is only expressed in dermal cell types (Figure 5c). Finally, we 234 
further investigated the correlation of these gene pairs in the replication dataset. These data show that 235 
the CTBP1 and OTUD6B gene pairs also display a significant correlation (r > 0.8, P <0.001 for both 236 
gene pairs) in the replication dataset (Supplementary Figure 6) while the correlation for AGAP2 is 237 
absent in the replication dataset (r = 0.21). These results seem to coincide with the tissue-specific 238 
expression data obtained from FANTOM5 were a positive correlation between AGAP2-AS1 and 239 
AGAP2 is also absent. Altogether, we identified non-coding genes that are expressed in cell-types 240 
relevant for SSc and of which the levels are altered in a disease specific manner in the skin of SSc 241 
patients.  242 
 243 
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DISCUSSION 244 
Our results using next generation sequencing firstly confirmed previous studies using microarrays and 245 
confirmed an inflammatory signature in the skin of early SSC patients. In addition to the analyses on 246 
coding genes, we report an in-depth analysis of deregulated lncRNAs in skin tissue from SSc patients. 247 
The top-3 deregulated antisense genes included CTBP1-AS2, OTUD6B-AS1 and AGAP2-AS1, and 248 
these findings were replicated in an independent dataset and further validated by qPCR. The 249 
expression of these lncRNAs is clearly distinct in patients, although the functional consequences of 250 
these deregulations are at this point difficult to infer given the limited information available on their 251 
potential functions. Future in-depth functional analyses are warranted on the functional roles of these 252 
genes to confirm their role in SSc pathogenesis. 253 
lncRNAs play an important role in development and disease (Batista and Chang 2013; Esteller 2011), 254 
but have not yet been described in relation to SSc. Most lncRNAs are not yet available on microarrays 255 
and are therefore missed in the available data sets that were investigating SSc deregulated genes. 256 
More importantly, association of lncRNAs with inflammatory diseases like rheumatoid arthritis, 257 
diabetes and psoriasis are increasingly being reported, highlighting their potential role in disease 258 
mechanisms (Gupta et al. 2016; Messemaker, Huizinga, and Kurreeman 2015). Here, we identify 676 259 
lncRNAs that are deregulated in skin from SSc patients as compared to healthy individuals. A 260 
large proportion of the deregulated lncRNAs belonged to the antisense RNA category. Antisense 261 
RNAs which reside in a locus with a sense gene (and often span part of this gene) and potentially 262 
function as co-regulators of the sense gene (Chan et al. 2015; Kimura et al. 2013; Peng et al. 2015). 263 
We identified 26 SAS gene pairs which displayed evidence of differential expression in SSc patients 264 
versus controls. From these gene pairs, 55% of the antisense genes showed similar direction of 265 
association in an independent data set. The top three deregulated antisense genes included CTBP1-266 
AS2, OTUD6B-AS1 and AGAP2-AS1. OTUD6B is a deubiquitinating enzyme of which little is 267 
known. Its downregulation has been linked to cell proliferation in B cells following prolonged 268 
cytokine stimulation (Xu et al. 2011). CTBP1 is a C terminal binding protein which acts as a 269 
transcriptional corepressor and plays a role in epidermal development (Boxer et al. 2014). Increased 270 
CTBP1 levels were shown to disrupt skin homeostasis (Deng et al. 2014). AGAP2 was found 271 
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upregulated in various cancers and is involved in focal adhesion and cell migration (Jia et al. 2016; 272 
Zhu et al. 2009). Interestingly, AGAP2-AS1 was also shown to be involved in cell migration and is 273 
able to repress transcription via interaction with EZH2 and LSD1 in cancer cells (Li et al. 2016).  274 
Based on our data, we believe that future studies on functional roles of lncRNAs in SSc pathogenesis 275 
might focus on CTBP1-AS2, OTUD6B-AS1 and AGAP2-AS1 as these were significantly 276 
deregulated, the deregulation was also found in an independent dataset, and based on current 277 
knowledge a role in pathophysiology is plausible. Thereby, one should take into account that we have 278 
investigated deregulated polyA-positive lncRNAs, while also polyA-negative lncRNAs exists 279 
(Derrien et al. 2012). Although polyA-negative lncRNAs are less well-studied, we do hypothesize that 280 
also these lncRNAs might play important roles in SSc development and require further investigation 281 
(Yang et al. 2011). 282 
 283 
With respect to coding genes, we observe an inflammatory signature, in line with previous research 284 
that shows the presence of an interferon/inflammatory signature in early SSc patients (Johnson et al. 285 
2015). In contrast to previous research, a clear TGF-β signal did not come forward from our gene list, 286 
despite the increase of fibrosis related-genes as ACTA1 and COMP (Farina et al. 2009b). When 287 
comparing genes from our study with a previous published dataset, a small proportion of genes (n = 288 
619) overlaps suggesting that consistent deregulated genes exist despite SSc-well known disease 289 
heterogeneity, large differences in the mean age and disease duration of patients between both studies 290 
(Supplementary Table 2). Moreover, an additional comparison with 415 genes obtained from a meta-291 
analysis performed by Lofgren et al show that 159 genes overlapped (38%)(Lofgren et al. 2016).  292 
 We investigated specific SSc-gene sets in more detail to identify genes deregulated in early SSc 293 
patients. Our study reports several coding genes which have not previously been highlighted in gene 294 
expression studies of SSc. COL4 (COL4A1, COL4A2 and COL4A4), is a gene in the collagen family 295 
and is a major component of the dermal-epidermal junction. Elevated levels of COL4 protein have 296 
been found in the serum of SSc patients (Gerstmeier H, Gabrielli A, Meurer M, Brocks D, Braun-297 
Falco O 1988) and COL4 autoantibodies have been found in 31% of SSc patients highlighting that an 298 
increase of COL4 might play a role in SSc (Riente et al. 1995). KRT4 and KRT9, overexpressed 299 
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genes from our study are normally not expressed in forearm skin. KRT4 is expressed in mucosal 300 
tissue and is increased upon inflammation (Bosch et al. 1989), while KRT9 is normally expressed in 301 
soles and hand palms (Rinn et al. 2008). KRT9 is required for structural integrity of the epidermis and 302 
KRT9 was found increased in psoriasis patients (Fu et al. 2014; Kim et al. 2016). The increased 303 
expression of these keratins in skin of early SSc patients highlights the possibility of aberrant 304 
activation of these genes early in disease.  305 
 Besides collagen and keratin genes, we also identified inflammatory genes. Some of these 306 
deregulated inflammatory genes are located in loci that are genetically associated to SSc including 307 
HLA and TNFAIP3 (Dieudé et al. 2010). Interestingly, the expression of TNFAIP3 is strongly reduced 308 
in SSc skin tissue. Given the role of TNFAIP3 as a negative regulator of NF-κB signalling, its 309 
downregulation would be suggestive of an increased NF-κB activation, possibly further enhancing the 310 
increased pro-inflammatory environment. TNFAIP3 was also found deregulated in several other cell 311 
types and suggests that genes and pathways are deregulated across multiple tissues(Avouac et al. 312 
2011). In line with this, we have also observed clusters of macrophages in our SSc skin biopsies. Also 313 
increased CX3CR1 expression came forward and likely contributes to skin inflammation in SSc as 314 
CX3CR1 knockout experiments resulted in decreased skin inflammation (Morimura et al. 2016). 315 
Interestingly, the top deregulated chemokines were CXCL2 and PF4 (CXCL4). CXCL2, a neutrophil 316 
chemoattractant and pro-angiogenic factor (Raman, Sobolik-Delmaire, and Richmond 2011), was 317 
reduced and might influence vascular repair within skin of SSc patients (Hummers et al. 2009). PF4 318 
(CXCL4) was increased at the RNA level and increased PF4 protein levels were found in SSc serum 319 
and skin (van Bon et al. 2014). Our study suggests that despite the short disease duration of the 320 
patients included in this study, distinct gene expression profiles already exist at an earlier stage in the 321 
disease process than investigated so far. Further studies in larger sample sets and long-term follow-up 322 
of patients should yield deeper insight into which relevant mechanisms are deregulated in what stage 323 
of the disease.  324 
  In conclusion, we here report a gene list of 619 genes consistently deregulated over two 325 
studies accounting for direction of association and providing a basis of consistent gene expression 326 
changes. We show that the expression of keratin genes is increased and that patients display enhanced 327 
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levels of genes originating from inflammatory gene signatures. In addition, we here provide a 328 
blueprint of DE lncRNAs which may play a role as underlying regulators disturbing processes 329 
contributing to SSc. Interestingly, even though many of these DE lncRNAs have to our knowledge not 330 
yet been described in context of SSc, we show strong correlations with coding genes for several 331 
antisense genes. Given the replication in an independent cohort, future studies on the functional role 332 
of these specific lncRNAs in SSc pathogenesis are warranted. 333 
 334 
 335 
MATERIALS AND METHODS 336 
For full details of methods see online supplementary material. 337 
 338 
Patient information 339 
Early SSc patients (with a disease duration < 2 years) were recruited at the Department of 340 
Rheumatology of the Leiden University Medical Center (Leiden, The Netherlands) and all patients 341 
met the American Rheumatism Association classification criteria for SSc (Subcommittee for 342 
scleroderma criteria 1980). Patient characteristics can be found in Supplementary Table 3. 343 
Institutional review board approval and written informed consent was obtained before patients entered 344 
this study. Two 4 mm skin biopsies were taken and from 10 patients the skin biopsy came from a 345 
clinically affected area and in 4 patients the skin was locally unaffected. Skin biopsies from healthy 346 
individuals were commercially sourced (Tissue Solutions, UK), came from surgeries of arm and leg 347 
and were age and sex-matched. 348 
 349 
Transcriptome characterisation and analysis 350 
RNA was isolated from skin biopsies and sequenced using polyA selection and a stranded 351 
protocol using Ion Torrent next generation sequencing technology (Service XS, The Netherlands). 352 
Reads were aligned to the human genome (Homo sapiens GRh38.78) using Bowtie2 and STAR and 353 
differential expression analysis was carried out using HTseq and DEseq2. All genes with a minimum 354 
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base mean expression value of 2.3 were included in the differential expression analysis. RNA 355 
sequencing files are deposited at the EGA-database under nr: EGAO00000000316 356 
(https://www.ebi.ac.uk/ega/organisations/EGAO00000000316). 357 
 358 
Publicly available gene expression datasets and gene sets analysis 359 
DE genes [FDR < 0.05, FC > 1.5] were compared with a publicly available dataset obtained from 360 
Assassi et al. (Assassi et al. 2015). DE genes were investigated via Gene Ontology (GO)-term 361 
analysis using Toppgene [version 23 may 2016] and in specific gene sets. Gene sets were obtained 362 
from Hugo Gene Nomenclature Committee (HGNC) or by additionally compiled SSc gene sets from 363 
alternative sources. Genes in the interferon and alternative macrophage activation signature were 364 
obtained from Mahoney et al. (Mahoney et al. 2015). Genes involved in TGFβ signalling were 365 
obtained from the Broad Institute. All genes included in these gene sets are outlined in Supplementary 366 
File 1. 367 
 368 
Long non-coding RNAs 369 
Genes annotated as lncRNAs (and sub classifications) were obtained from GENCODE (Ensemble 370 
version 82) (Harrow et al. 2012). Antisense genes were linked to sense genes on the basis of 371 
annotations from GENCODE (Harrow et al. 2012). Antisense genes with a concomitant DE sense 372 
gene were investigated in an as yet unpublished RNA sequencing dataset of skin biopsies of 14 SSc 373 
patients and 6 healthy individuals. An overall combined p-value was calculated using Fisher’s exact 374 
test. The top three sense and antisense genes were visualised in IGV to ensure strand specificity and 375 
non-overlapping reads (Supplementary Figure 7). The coding potential of antisense genes was 376 
determined using an in-silico coding potential calculator (Kong et al. 2007) and analysis of cell 377 
specific expression was performed using publicly available FANTOM5 datasets 378 
(http://fantom.gsc.riken.jp/5/) (Lizio et al. 2015; Severin et al. 2014). Correlations between antisense 379 
and sense genes were calculated using variance stabilised transformed (VST) counts by spearman 380 
rank test.  381 
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 574 
Table 1. Replication of 22 antisense genes in an independent RNA-seq dataset. The table includes, Fold 
changes (Log2FC) and p-values (P) from both studies and a combined p-value. Combined p-values were not 
calculated for the genes with opposite direction of association according to Rau et al. 2014 (Rau, Marot, and 
Jaffrézic 2014). 
 Dataset 1 Dataset 2  
Gene Log2FC P FDR log2FC  P Combined 
CTBP1-AS2 0,32 0,012 0,044 0,40 7,5E-07 1,1E-09 
OTUD6B-AS1 -0,95 7,0E-05 0,001 -0,63 0,001 1,4E-08 
AGAP2-AS1 0,50 0,006 0,027 0,34 0,002 1,7E-06 
HAND2-AS1 -1,04 0,002 0,011 -0,63 0,007 2,1E-06 
HMGN3-AS1 -0,64 0,009 0,034 -0,33 0,017 2,6E-05 
ZBTB11-AS1 0,53 0,002 0,010 0,17 0,143 4,5E-05 
NIFK-AS1 -0,56 0,006 0,027 -0,36 0,178 2,3E-04 
WAC-AS1 -0,58 0,001 0,009 -0,17 0,217 5,9E-05 
PIK3CD-AS2 1,50 5,1E-06 1,5E-04 0,18 0,407 3,1E-07 
ARRDC1-AS1 0,43 0,012 0,045 0,13 0,411 0,001 
ZNF252P-AS1 1,64 1,1E-04 0,001 0,19 0,422 7,8E-06 
SBF2-AS1 -0,43 0,014 0,049 -0,06 0,715 0,002 
UNC5B-AS1 1,52 5,6E-05 0,001 -0,76 0,007 NA 
HOXA10-AS -2,64 4,4E-11 1,3E-08 0,53 0,056 NA 
SLC25A25-AS1 0,52 4,3E-04 0,004 -0,30 0,163 NA 
RUNDC3A-AS1 0,92 0,001 0,005 -0,30 0,225 NA 
ZBED5-AS1 0,45 0,012 0,044 -0,16 0,275 NA 
LOXL1-AS1 0,80 5,6E-05 0,001 -0,22 0,408 NA 
BRWD1-AS2 1,54 3,4E-07 2,0E-05 -0,14 0,514 NA 
ZEB1-AS1 -0,67 0,003 0,015 0,06 0,738 NA 
RGMB-AS1 0,78 0,005 0,023 -0,05 0,815 NA 
TMPO-AS1 1,40 7,4E-08 5,8E-06 -0,02 0,923 NA 
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 576 
 577 
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Figure 1. DE genes overlap with a previous microarray study and reveals consistent deregulated 578 
pathways. (a) Venn diagram comparing DE genes in SSc patients versus controls from the current study (n = 579 
4901 DE genes) with a microarray study from Assassi et al. (n = 2417 DE genes). (b) Directionality of 619 580 
consistently deregulated genes from the two studies displayed as mean fold change (mean ± SE). Genes up or 581 
down regulated from Assassi et al were selected and plotted. The concomitant fold changes of these genes from 582 
our study were also plotted indicating similar directionality in both studies. (c) Top 5 Biological processes GO-583 
terms enriched using genes that are upregulated in SSc patients from the two studies. 584 
 585 
Figure 2. Analysis of DE genes of specific SSc gene sets. Volcano plots showing differential expression within 586 
the 6 genesets: TGFβ signalling (a, n=86 genes), collagen (b, n=46 genes), keratin (c, n=76 genes), interferon 587 
(d, n=50 genes), alternative macrophage activation (e, n=60 genes) and chemokine (f, n=84 genes). Genes 588 
depicted in red were significantly deregulated (Benjamini Hochberg-corrected p-value < 0.05). RNA levels 589 
(VST count) of individuals genes in healthy controls and SSc patients for COL4A4 (g), KRT4 (h), KRT9 (i), 590 
TNFAIP3 (j), CX3CR1 (k), CXCL2 (l), and PF4 (m). p-values represent Benjamini-Hochberg-corrected p-591 
values. The mean ±SD of each group is depicted in the graphs. 592 
 593 
Figure 3. DE lncRNAs in SSc patients in comparison with healthy controls. (a) Heatmap depicting the Z-594 
scores of 676 deregulated lncRNAs. Red colour indicates low expression and the yellow colour indicates high 595 
expression. (b) Volcano plot showing top deregulated lncRNAs by fold change (log2) on the x-axis and the p-596 
value (-log10) on the y-axis. (c) Deregulated lncRNAs (n = 676) divided by subclasses. (d) Venn diagram and 597 
scatter plot showing the proportion of significant gene pairs (Benjamini Hochberg-corrected p-value < 0.05). 598 
Significant DE gene pairs are depicted in red and depicting the fold change (log2) of both the sense and 599 
antisense genes. e, Absolute spearman rank correlation between sense and antisense genes within SSc gene pairs 600 
and gene pairs not deregulated in SSc.  601 
 602 
Figure 4. Top 3 replicated antisense genes show strong correlation with their sense coding gene. (a-c) VST 603 
count values of top 3 replicated SAS gene pairs: CTBP1 (a), OTUD6B (b) and AGAP2 (c) in SSc patients (n = 604 
14) and controls (n = 6) p-values are Benjamini-Hochberg corrected and were generated via DEseq2. (d-f) 605 
Correlation between sense and antisense genes within a gene pair for CTBP1 (d), OTUD6B (e) and AGAP2 (f). 606 
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Count values are divided into healthy, unaffected or affected skin tissue. Spearman rank test was used to 607 
calculate correlations between the sense and antisense gene. 608 
 609 
Figure 5. Cell type specific expression of SAS gene pairs in dermal and immune cells. Expression levels for 610 
CTBP1 and CTBP1-AS2 (a), OTUD6B and OTUD6B-AS1 (b) and AGAP2 and AGAP2-AS1 (c) in dermal and 611 
immune cell types. Expression values are shown as TPM for both the sense and antisense gene. Expression 612 
values of each cell type was measured in at least 3 donors. Correlation analysis was performed by spearman 613 
rank test.  614 
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